TABLE 1.

PAEs of telavancin for 16 strains

Strain description	MIC (μg/ml)	PAEsb (h)	Duration of effect (h)a
			0.2 ×MIC		0.3 ×MIC		0.4 ×MIC
			SMEsc	PA-SMEsd	SMEs	PA-SMEs	SMEs	PA-SMEs
MRSA
Vancomycin susceptible
ATCC 33591	0.25	1.5, 2.0	0.3, 0.3	7.7, 8.0	1.4, 1.4	>10.0, >10.3	2.3, 3.5	>10.0, >10.3
SA 1130	0.12	1.4, 1.6	0, 0.4	5.4, 5.8	2.0, 4.4	10.0, >10.5	6.5, 6.9	>10.0, >10.5
SA 1307	0.12	1.1, 1.6	1.1, 1.0	6.0, 6.4	2.6, 3.1	>10.5, >10.6	6.3, 6.5	>10.5, >10.6
SA 1316	0.12	1.8, 2.0	0.7, 1.1	2.9, 3.1	5.1, 5.2	5.4, 5.6	6.0, 6.1	>10.7, >10.6
Heterogeneous vancomycin intermediate
SA 618	0.12	1.7, 2.4	0.3, 0.8	5.7, 6.5	1.5, 1.6	8.3, 9.8	2.3, 4.3	10.3, >10.3
SA 873	0.12	1.2, 1.6	0, 0.3	3.6, 4.0	0.5, 0.8	4.8, 6.0	1.0, 1.8	6.7, 7.0
Vancomycin intermediate
SA 555	0.5	3.4, 3.9	0.3, 0.3	5.9, 6.0	1.7, 2.3	10.3, >10.6	4.3, 5.4	>10.3, >10.6
SA 770	0.25	1.6, 2.3	0.7, 0.8	3.8, 5.0	0.8, 1.8	6.3, 8.3	0.8, 1.9	9.6, >10.7
SA 1287	0.5	1.2, 1.8	0, 0.3	5.1, 5.2	0.4, 0.7	8.6, 10.0	0.8, 1.2	>10.3, >10.0
SA 1984	0.25	0.9, 1.4	1.0, 1.0	6.8, 8.6	2.6, 3.0	>10.0, >10.6	10, 10.6	>10.0, >10.6
Vancomycin resistant
SA 510	0.5	1.3, 2.0	1.9, 2.5	5.6, 5.8	2.3, 3.1	6.0, 6.6	3.6, 5.0	8.1, 8.8
Streptococcus pyogenes HMC 414	0.06	6.1, 6.7	0,0	8.7,10.7	0, 0.4	>10.7, >10.7	0.4, 0.7	>10.7, >10.7
Streptococcus agalactiae HMC 5	0.12	0.4, 1.0	0.2, 0.4	0.8, 2.1	2.1, 2.7	4.7, 6.2	>10.7, >11.0	>10.7, >11.0
Enterococcus faecalis ATCC 29212	0.25	0.3, 0.7	0.8, 0.7	5.3, 5.8	2.0, 2.8	>10.7, >10.8	3.6, 4.0	>10.7, >10.8
Enterococcus faecalis HMC 571	0.25	1.5, 2.2	0.1, 0.6	3.9, 5.1	2.6, 3.2	7.2, 7.6	9.6, 10.0	>10.6, >10.8
Enterococcus faecium HMC 588	0.12	1.2, 1.6	1.2, 1.8	1.9, 2.2	7.2, 7.7	8.9, 9.3	8.8 9.9	>10.0, >10.5

^aValues are those obtained from two separate experiments.

^bStrains were exposed to 10 times the MIC of telavancin (see text) for 1 h at 35°C. The drug was removed by 1:1,000 dilution.

^cStrains not previously exposed to telavancin.

^dStrains previously exposed to telavancin.